Triumvira Immunologics
PrivateLast Round
Series A
Extension
Mar 17, 2022
Total Funding Raised
$145M
Company Overview
Triumvira Immunologics is a biotechnology company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Triumvira Immunologics Comparables
Compare Triumvira Immunologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WindMIL Therapeutics | 83% | |
| A2 Biotherapeutics | 81% | |
| Adaptimmune Therapeutics | 78% |
Triumvira Immunologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 17, 2022 | ||||
| Series A | Aug 27, 2020 |
Key People
Founding team and executive leadership
Triumvira Immunologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| B Capital Group | Series A, Series A Extension |
| Oceanpine Capital | Series A |
| Northpond Ventures | Series A |
| Bloom Burton & Co. | Series A, Series A Extension |
| Viva Biotech | Series A |
| Northpond Ventures | Series A Extension, Series A |
| ATEM Capital | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 37% MoM, from 2.2K to 3K.
- Mar 13, 2025
Will present updated clinical data at the 2025 SITC Spring Scientific Conference.
Triumvira Immunologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Triumvira Immunologics's valuation, stock price, and market status.
Is Triumvira Immunologics a public or private company?
Triumvira Immunologics is a private company.
What is the current stock price of Triumvira Immunologics?
Triumvira Immunologics is a private company with no public stock price. No recent secondary market data is available.
How much is Triumvira Immunologics worth (valuation)?
Valuation information for Triumvira Immunologics is not publicly available.
Can I buy Triumvira Immunologics stock?
Triumvira Immunologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Triumvira Immunologics's last funding round?
Triumvira Immunologics's most recent funding round was Series A Extension on March 17, 2022.
Who are the main investors in Triumvira Immunologics?
Key investors in Triumvira Immunologics include Northpond Ventures, Northpond Ventures, Leaps by Bayer.
Will Triumvira Immunologics IPO soon?
No public IPO plans have been announced for Triumvira Immunologics.
How can I track Triumvira Immunologics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Triumvira Immunologics's secondary market activity and sign up for updates.